Dr. Teodor Duro, MD

Dr. Duro practices at NorthBay Medical Center in Fairfield, California, part of NorthBay Healthcare.

Dr. Duro's NPI, 1780180315, was assigned on April 3, 2018. Dr. Duro holds New Mexico license MD2021-0170.

Dr. Duro's primary practice is NorthBay Medical Center, at 1200 B Gale Wilson Blvd, Fairfield, CA 94533 in Solano County. The practice phone is (707) 646-5000.

Dr. Duro's primary practice is NorthBay Medical Center in Fairfield, California, part of NorthBay Healthcare. Dr. Duro is also affiliated with University of New Mexico Hospital. The medical group on file is NorthBay Medical Center. Dmand AI also links Dr. Duro to 3 more medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Duro practices, 4 sites in all. Vendor and product names are available with a free account.

Endocrinology, diabetes and metabolism is Dr. Duro's primary specialty in the NPI Registry, under taxonomy code 207RE0101X. Dr. Duro is licensed in New Mexico.

CMS data shows 167 Medicare services from Dr. Duro across 5 procedure codes in 2024, for 101 Medicare patients. Medicare paid $9,709 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 101 Medicare patients who saw Dr. Duro in 2024. The largest group is 65 to 74, with 53 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Duro's median patient age at 62, with 66% women.

In 2024, Dr. Duro wrote 479 Medicare Part D claims for 99 patients. 52% of them were for generic drugs. CMS names the drug for 272 of them, across 12 drugs with 11 or more claims each, at $76,746 in total drug cost. In 2023, CMS named 117 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Duro for performance year 2024, reported as part of a group. Dr. Duro accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Duro as offering telehealth.

Dmand AI links 6 papers to Dr. Duro, published from 2022 to 2024. 2022 was the busiest year, with 4. The most frequent topics are Cardiovascular Diseases. Dr. Duro has published most often in Am J Med. Dr. Duro's most frequent co-authors are David S. Schade, Allen B. Adolphe, MD and Kristen L. Gonzales, MD.

CMS Open Payments shows 34 general payments to Dr. Duro from 15 drug and device companies from 2021 to 2025. Speaker and faculty fees make up the largest share, 55% of the total. Sanofi and Genzyme US Companies paid the most, $3,713.